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Historically, the introduction of classical bone marrow transplantation into this country some thirty years ago centered on adults with 
problems in the form of rejection and acute and chronic 
grafttversusthost disease contributing to morbidity and 
mortality.1,2 Despite our early involvement in the use of 
cyclosporine A as a new generation immunosuppressive 
agent, these complications continued, although of det
creased incidence and severity.3 The major advance in 
their reversal was initiation of a series of studies that 
eventually led to the landmark description of ex vivo 
Ttcell depletion using Campath monoclonal antibodt
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INTRODUCTION AND STUDY DESIGN: We conducted a retrospective analysis of consecutive referrals of pa-
tients under 18 years of age undergoing immunohematopoietic stem cell transplantation to assess the influence 
of age, diagnosis, graft type and gender on survival. We also contrasted program activity and outcome to that 
reported from a state hospital in the same geographical area over a comparable period.
METHODS: conditioning employed either a sequential combination of fractionated 12Gy whole body and 6Gy 
total nodal irradiation separated by 120mg/kg of cyclophosphamide in patients over 15 years of age. alternatively, 
the latter agent was combined initially with oral busulphan and later the intravenous equivalent. neuroblastoma 
cases were prepared using a different regimen. in allografts the harvested product underwent ex vivo t-cell deple-
tion with the humanized version of anti-cd 52 monoclonal antibody designated campath 1h. no additional 
immunosuppression was given except where matched unrelated volunteer donors were employed. 
RESULTS: sixty-eight procedures were carried out in 61 patients over a 6-year period. of 11 with acute myeloid 
leukemia, 8 are alive and well whereas 8 of the 14 with the lymphoblastic variant have died. of the remaining 12 
with hematologic malignancy, all but 2 are alive. ten of the 17 with aplasia are alive as are all with thalassemia 
or sickle cell disease. none of the four variables tested affected survival. 
CONCLUSION: our analysis indicates that the standardized preparative regimen, coupled with a now well-es-
tablished immunosuppressive regimen, is as effective in patients under 18 years of age as in adults. our analysis 
also indicates that in a resource-scarce or developing country, it is mandatory to limit high-risk and relatively 
expensive procedures to active teams that enjoy international accreditation, whether these be in the state or 
private sector. 
ies4 and our experience continues to accummulate.5t7 
Notwithstanding the unquestioned benefits, and in 
contrast to elsewhere in the world, there remained a subt
stantial local resistance to subjecting children to what 
was perceived as a still unduly hazardous undertaking! 
Nevertheless, within 10 years of commencement, it bet
came more generally appreciated that idiopathic and 
irreversible aplasia could only be cured by allografting 
whereas a variable response was obtained with antit
lymphocyte globulin and hightdose methylprednisot
lone.8,9 From that time the eligibility for grafting was 
modified to accommodate younger cases and our initial 
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results that were reported whilst still at Groote Schuur 
Hospital10t12 have recently been updated.13
From January 1995, our established and approved 
protocols were transferred in toto to a custom built 
facility in the private sector. In the new location cont
secutive procedures continue to be reported to the 
Center for International Blood and Marrow Transplant 
Research and this specific team was again retaccredt
ited in January 2003, thereby maintaining a 30tyear 
unbroken record of achievement. Thus, the following 
analysis from the Department of Haematology and the 
Bone Marrow Transplantation Unit incorporating The 
Searll Research Laboratory for Cellular and Molecular 
Biology at the Constantiaberg MeditClinic brings int
ternational perspective to outcomes in the pediatric age 
group undergoing immunohematopoietic grafting in 
South Africa.
The available facilities, when we pioneered the use 
of this technology in the Groote Schuur Hospital at 
the beginning of 1972, were such that management 
of the young was logistically difficult. This hurdle was 
overcome by providing separate rooms when the newly 
dedicated reverse isolation unit was designed and then 
commissioned in 1982. Given the upgraded physical 
plant, and expansion of staff to include a social worker, 
a physician and a psychiatrist with interest in adolest
cents, it became a realistic option with the first child 
grafted in 1978. The multitdisciplinary approach was 
consolidated by participation of Dr Paul Rogers followt
ing his return after a period of overseas postgraduate 
training.14, 15
With the relocation of this fully integrated group to 
an independent academic center it was soon demont
strated, both logistically and functionally, that there was 
no impediment to providing costly and high technology 
activities in such an environment.16t18 Continuing outt
come analysis from this reverse isolation unit, staffed by 
nurses trained in all relevant facets with a virtually fullt
time commitment from pediatricians already in the host
pital, rapidly confirmed the feasibility of using advanced 
protocols approved by Institutional Review Board for 
conventionally defined indications, in a protected envit
ronment dedicated to tertiary hematologic care.17
In the last decade a number of refinements have 
become standard practice. Among these was the use 
of matched or minimally mismatched family memt
bers and the availability of donations from histocomt
patible, unrelated volunteers via the South African 
Marrow Donor Registry.18 To this end, center desigt
nation by the European Group for Blood and Marrow 
Transplantation19 and by the National Marrow Donor 
Programme followed.20
A priority remains the commitment to whatever 
innovation is necessary to keep abreast of relevant adt
vances such as the study of chimerism using short tert
minal repeat assay.21 This has included exploring the 
role in thalassemia, sickle cell disease,22 mucopolysact
charidoses,23 common variable immunodeficiency,24 
and Fanconi anaemia.25,26 The latter is currently linked 
to gene therapy being evaluated jointly with Professor 
Chris Walsh initially in North Carolina,27 and now curt
rently in New York, where special attention has been 
given to complications from older forms of conditiont
ing that included cyclophosphamide or, even earlier, rat
diotherapy. Accordingly, this phase has been revised to 
the use of fludarabine and intravenous busulphan.28
The latter model is to be tested as the basis for cont
trasting the previously favored myeloablative combinat
tions to primarily immunosuppressive options across 
the age spectrum.29,30 The rationale for this focus lies 
in harnessing the formidable capacity of the immune 
system to identify and eradicate tumor cells and cret
ates a platform for the use of immunotherapy based on 
subsequent delayed or donor lymphocyte infusions.31 
Whether such a theoretically attractive modification 
will represent a significant advance awaits longer follow 
up.32
Among the remaining challenges is the problem of 
mucositis, which impairs nutritional intake, and has 
led to a focus on the need for developing a structured 
approach to nasojejunal feeding rather than the more 
traditional total parenteral approach (Wood, O’Keefe, 
Jacobs, Dubrovskaya, unpublished) Additionally, there 
is an increasing appreciation of infections particularly 
cytomegaloviremia that may progress to organ involvet
ment as in pneumonitis and this, together with other 
infections, possibly related to the use of monoclonal ant
tibodies,33t35 predicated the ongoing study of immunot
logic reconstitution and viral surveillance with proactive 
ganciclovir therapy.36 
It is against this brief historical outline that outcome 
in children is presented: the corresponding results in 
those over 18 years are in preparation ( Jacobs, Wood, 
Juritz, unpublished).
STUDY DESIGN 
Our analysis is tabulated for consecutive entries seen 
in the 6tyear period to allow comparison to updated 
results from the State.13 Additionally, we explored the 
practicality of operating such a facility, with the specific 
focus on childhood referrals, outside the confines of the 
usual base in teaching hospitals. With appropriate att
tention to financial imperatives and, notwithstanding 
the evertconstricting focus of changing health care, it 
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also tests the possibility of maintaining, and continut
ally developing new aspects of this technology in more 
innovative indications, to keep abreast of worldwide 
advances.37,38
One modification has been a switch from oral to int
travenous busulphan.39 A further logical step will now 
be the increasing use of fludarabine as a component of 
minit or sotcalled reducedtintensity conditioning regit
mens that have, as a backbone, sufficient suppression 
of the immune system primarily to allow host accept
tance of the incoming graft. The anticipation is that 
a grafttversustleukemia effect will be retained whilst, 
at the same time, the more serious consequences of 
the classical myeloablative regimens will decrease.40 
Furthermore, in addition to confirming the pattern of 
hematopoietic reconstitution, a secondary endtpoint is 
that of defining immunologic reconstitution.41,42 This 
endeavor aims to decrease the hazards of infection that 
notably include those attributable to cytomegalovit
rus.43,44
METHODS
After recording a detailed history and completing a 
physical assessment, standard hematologic procedures 
were employed for a full blood count,45 aspiration and 
trephine biopsy.46 The malignancies were classified ust
ing conventional cytomorphology supplemented by 
flow cytometry47 and cytogenetics48 to precisely det
lineate each case after which treatment was by riskt
stratification to standardized protocols.49,50 The mat
lignancies were classified according to World Health 
Organization criteria.51 Aplasia was similarly categot
rized and in those with Fanconi anaemia, additional 
studies included chromosomal fragility after exposure 
to clastogenic agents.52 Hemoglobinopathy was subdit
vided by electropheresis and appropriate biochemical 
tests.53
For donor selection, histocompatibility testing 
employed conventional methodology and matching 
between donor and recipient using international stant
dards via the Hub center of the South African Bone 
Marrow Donor Registry.19 Donations for matched 
unrelated volunteers were provided in collaboration 
with the Anthony Nolan, Australian, German and 
Leiden Groups as well as The National Marrow Donor 
Programme.21
All aspects of the treatment including indication, 
anticipated benefits and potential risks were fully ext
plained by means of extensive counseling after which 
written informed consent was obtained. Recipients and 
donors were assessed to ensure suitability for particit
pation and this included clinical examination and nont
invasive cardiac and respiratory testing. Placement of 
a doubletlumen catheter54,55 was followed by nursing 
in reverse isolation.56 Selective decontamination of the 
bowel was performed with daily fluoroquinolone57 and 
oral prophylaxis for cytomegalovirus and Pneumocystis 
carinii, respectively, with acylclovir or valaciclovir58 and 
cottrimoxazole, or in the case of allergy, an appropriate 
equivalent.59
Conditioning was 12 Gy fractionated total body irt
radiation over 3 days at rates of approximately 10cGy 
per minute, 60 mg/kg of cyclophosphamide over 2 days 
with intensive hydration, protection of the urothelium 
with mesnum and total nodal irradiation at 1.5 Gy over 
2 days.4 The alternative regimen comprised 120 mg/kg 
of cyclophosphamide combined with 16 mg/kg of oral 
busulphan,4,60 or 3.2 mg/kg per day intravenously for 
4 days. Patients with Fanconi anemia received cyclot
phosphamide at reduced doses.61 Irrespective of body 
weight, a quantitative and qualitatively adequate hart
vest was obtained after mobilization with stimulatory 
peptides for 5 consecutive days, by using constantly 
upgraded aphaeresis technology on the Cobe Spectra 
as previously described.62,63
No prophylaxis was employed against grafttversust
host disease except in those undergoing matched unt
related donations where cyclosporine was maintained 
at a therapeutic level for 6 months using the C2 assay64 
and then tapered to zero over the following half year. 
Nutrition was a high priority and, whilst intravenous 
supplementation was not used, there was early recourse 
to finetbore nasojejunal tube feeding when needed,65,66 
(Wood, O’Keefe, Dubrowsky, Vincent, Jacobs, unpubt
lished).
Comparisons of results between the state and prit
vate hospital were made using Pearson’s chitsquared 
tests. Survival time after transplant between groups 
was assessed using KaplantMeier survival curves. 
Survival times between groups were compared using 
logtrank tests.
RESULTS
The total number of procedures including retranst
plants 68 at Constantiaberg MeditClinic and 31 at 
Groote Schuur Hospital. The median age of the pat
tients treated at Constantiaberg was 11.7 years (range 
1.7t18.7 years). Hematologic malignancy accounted 
for 37 cases at Constantiaberg MeditClinic (Table 1) 
and 16 at Groote Schuur Hospital. Benign conditions 
included aplasia (n=17 at Constantiaberg MeditClinic, 
n=11 at Groote Schuur Hospital) or miscellaneous 
conditions (n=14 at Constantiaberg MeditClinic, n=1 
at Groote Schuur Hospital) (Table 2). Apart from the 
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Table 1. patients with  hematologic malignancy treated at Constantiaberg Medi-Clinic.
Case No. Diagnosis Gender Interval to transplantation (months) Age Type of Graft Current status
 1 All M 10 16 Allograft Aspergillosis
 2 All M 25 15 MuD CCr
3 All F 7 16 Allograft CCr
4 All M 37 17 MuD Multiple organ failure
5 All F 7 17 MuD relapsed
6 All M 13 5 Autograft CCr
7 All F 39 6 Autograft relapsed
8 All F 27 5 Autograft relapsed
9 All F 33 13 Autograft relapsed
10 All M 6 16 Autograft CCr
11 All M 8 17 Autograft relapsed
12 All F 9 7 Autograft CCr
13 All M 43 13 Autograft relapsed
14 All F 8 14 Autograft CCr
15 AMl F 6 18 Allograft CCr
16 AMl M 5 3 Allograft CCr
17 AMl M 17 4 Allograft relapsed died
18 AMl F 3 15 Allograft CCr
19 AMl F 13 12 Allograft Cardiomyopathy - Died
20 AMl M 3 11 Allograft CCr
21 AMl F 6 15 Allograft CCr
22 AMl M 24 13 Allograft relapsed - Died (2nd)a 
23 AMl M 5 17 Allograft CCr
24 AMl F 7 14 Autograft CCr
25 AMl F 8 4 Autograft CCr
26 CGl F 11 13 Allograft CCr
27 CGl M 36 18 MuD CCr
28 CGl M 5 16 Autograft CCr
29 CGl F 9 14 Synegenic CCr
30 CGl M 19 14 MuD CMV pneumonitis
31 CMMl F 2 2 Allograft CCr
32 eT F 2 17 MuD CCr
33 Hl M 8 12 Allograft CCr
34 Hl M 11 14 Autograft CCr
35 nHl M 10 15 Autograft CCr
36 nHl F 23 9 Autograft Viral infection
37 T-Cell M 18 11 Allograft CCr
All=Acute lymphoblastic leukemia, AMl=Acute myeloblastic leukemia, CGl=Chronic granulocytic leukemia, CMMl=Chronic myelomonocytic leukemia, eT=essential thrombocythemia, Hl=Hodgkin lymphoma 
nHl=non-Hodgkin lymphoma, T-Cell=T-lineage lymphoma, MuD=Matched unrelated volunteer donor, CCr=Continuous complete remission, aDeath after a retransplant.
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Table 2. patients with benign hematologic conditions treated at Constantiaberg Medi-Clinic.
Case No. Diagnosis Gender Interval to transplantation (months) Age Type of Graft Current status
 38 AA M 3 11 Allograft CCr
 39 AA M 3 13 Allograft no engraftment
 40 AA M 10 13 Allograft Septicaemia
 41 AA M 2 18 Allograft CCr
 42 AA M 5 15 MuD CCr
 43 AA F 1 8 MuD ? VOD/Septicaemia
 44 Fan F 12 10 Allograft CCr
 45 Fan F 67 12 Allograft CCr
 46 Fan F 24 6 Allograft CCr
 47 Fan F 60 11 Allograft CCr
48 Fan M 29 7 Allograft no engraftment
49 Fan M 30 7 Allograft Septicaemia
50 Fan F −a 9 MuD CCr
51 Fan M 168 16 Allograft lymphoproliferative
52 Fan F 20 6 Allograft resp. and renal failure
53 Fan F 42 6 Allograft Multiorgan failure
54 Fan F 5 5 Allograft CCr
55 Germ cell tumor F 18 2 Allograft CMV pneumonitis
56 Hurlers M 21 3 MuD CCr
57 iGDS M 32 11 Allograft CCr
58 neuro F 9 4 Autograft CCr
59 neuro M 5 2 Autograft relapse
60 neuro M 6 15 Autograft CCr
61 neuro F 5 4 Autograft CCr
62 neuro M 5 3 Autograft CCr
63 Thal/Haem F 89 7 Allograft CCr
64 Thal/Haem M 108 10 Allograft CCr
65 Thal/Haem M 23 2 Allograft CCr
66 Thal/Haem M 63 16 Allograft Alive and disease-free
67 Thal/Haem F 57 6 Allograft CCr
68 Thal/Haem F 71 11 Allograft Alive and disease-free
AA=Aplastic anaemia, Fanconi=Fanconi anaemia, Germ Cell =Germ cell tumour, iGDS=immunodeficiency disease, neuro =neuroblastoma, Thal/Haem= Thalassaemia and haemoglobinopathies Muco=Mucopolys
accharidosis, CCr=Continuous complete remission, MuD=Matched unrelated volunteer donor, ainterval to transplantation unknown.
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larger numbers and additional indications in this series, 
the populations were comparable.13
Day 0 was designated as graft infusion. The median 
time to reach 0.5×109/L and 1.0×109/L neutrophils 
were 18 days (range, 9t34 days) and 28 days (range, 10t
59 days), respectively. The median time for platelets to 
reach 25×109/L and 100×109/L was 17 days (range, 
5t32 days) and 27 days (range 13t127 days), respect
tively.67,68 
Transplanttrelated mortality was death attributable 
to infection within the first 100 days in the absence of 
any disease recurrence29 and it accounted for all the 
events apart from one due to dilated cardiomyopathy. 
An unusual variant of the acute syndrome of graftt
versusthost disease occurred within the first 6 months 
that was distinctly different from the classical chronic 
disease.68,69 This was regarded as a forme fruste due to 
altered immune status consequent upon the ex vivo Tt
cell depletion70,71 and occurred in only two cases with 
successful reversal using topical steroids combined with 
a short course of oral prednisone.72,73 
Cytomegalovirus was demonstrated using the PP 65 
assay in two instances that were treated intravenously. 
One died and in the second no further isolates were 
present at two weeks although a further 14 days of outt
patient oral antiviral treatment followed. Anorexia with 
nausea and vomiting was readily controlled with serot
tonin and dopamine receptor antagonists although oct
casionally prochlorperazine was added.74 Diarrhea was 
assessed with stool culture and treatment of Clostridium 
difficile when present;75 otherwise simple motility modt
ulation using loperamide hydrochloride, a combination 
of kaolin with bismuth carbonate, pectin coupled to 
chlorodyne was used.76 Particular attention has focused 
on maintaining optimum fluid and electrolyte balance.77 
Pain was a major problem when mucositis occurred and 
initially required oral or intravenous opiates.78 This 
symptom has been dramatically reduced by the use of 
sucralfate.79 
Hematologic malignancies (Table 1) 
Acute myeloid leukemia (11 procedures, 10 patients 
at Constantiaberg MeditClinic) (9 procedures, 9 pat
tients at Groote Schuur Hospital), once diseasetfree, 
was treated on this regimen. Nine were allogeneic. One 
died from cardiomyopathy, a second died in relapse and 
a third died from recurrence after a second technically 
successful transplant. Acute lymphoblastic leukemia, 
most of whom were in second remission (14 procet
dures, 11 patients at Constantiaberg) (4 procedures, 4 
patients at Groote Schuur), were autografted in 9, of 
whom 5 died in relapse. Of the allografts (n=2) from 
siblings 1 died of aspergillosis. A further 3 employed 
matched unrelated volunteers with 1 dying from mult
tiorgan failure and 1 with recurrent disease. Patients 
with juvenile myelomonocytic leukemia (1 procedure, 
1 patient at Constantiaberg) (1 procedure, 1 patient 
at Groote Schuur) remain alive. Chronic granulocytic 
leukemia (6 procedures, 5 patients at Constantiaberg) 
(2 procedures, 2 patients at Groote Schuur Hospital) 
was autografted in one who did not achieve cytogenetic 
remission and after matched unrelated volunteer donat
tion achieved this status by molecular criteria. One synt
geneic, three sibling allografts and one further unrelated 
graft were successful of which one died from cytomegat
loviral pneumonitis. The remainder were disease free at 
the time of writing. Hodgkin (2 procedures, 2 patients 
at Constantiaberg) (n=0 at Groote Schuur) and other 
lymphomas (3 procedures, 3 patients at Constantiaberg) 
(n=0 at Groote Schuur) received allografts in 2 and aut
tologous reinfusion in 3 case. One died from infection 
and 4 remain in remission.
Benign Diseases (Table 2)
In cases of aplastic anaemia (6 procedures, 5 patients 
at Constantiaberg MeditClinic) (10 procedures, 7 pat
tients at Groote Schuur Hospital),4 were allografted 
and 3 were alive and well at the time of writing. One 
failed to engraft and despite a repeat procedure died 
from septicemia. Two received matched unrelated dot
nations; 1 died from septicemia and the other is well. 
Fanconi anemia cases (11 procedures, 10 patients at 
Constantiaberg) (5 procedures, 4 patients at Groote 
Schuur) were allografted. One required a second att
tempt and died with septicaemia, another developed 
secondary lymphoproliferative disorder and two died 
from cytomegaloviral infection and another from mult
tiorgan dysfunction. In this category, damage to the orot
pharynx and gastrointestinal tract made enteral feeding 
unreliable and added the costs for limited periods of tot
tal parenteral nutrition.80,81 Hemoglobinopathy (6 prot
cedures, 6 patients at Constantiaberg) (n=0 at Groote 
Schuur) were all allografted, and were alive and well at 
the time of writing although two still had disease prest
ent on sensitive biochemical testing.
A miscellaneous group was made up of 1 patient 
with germ cell tumor that was allografted and died 
from cytomegaloviral pneumonitis, and 5 patients with 
neuroblastoma that were autografted and 1 patient died 
with relapse. A further patient with mucopolysaccharit
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Figure 1. kaplan-Meier survival for all patients. kaplan-Meier 
analysis shows that at 6.8 years there is a stable plateau 
consistent with cure. it is notable that results are similar 
for idiopathic aplasia, Fanconi anaemia and acute myeloid 
leukaemia with non-significant differences for lymphoblastic 
leukemia and the remaining cases. There is also no difference 
in outcome for graft source, but a slight benefit for the female 
gender, which did not attain statistical significance.
dosis and another with immunodeficiency remained 
alive and well at the time of writing.
Overall Survival 
Overall survival was 60% at 7 years of followtup (n=59 
at Constantiaberg MeditClinic) (Figure 1). Notably, 
survival was similar for idiopathic aplasia, Fanconi anet
mia and acute myeloid leukemia with nontsignificant 
differences for lymphoblastic leukemia and the remaint
ing cases. There is also no difference in outcome by graft 
source, but a slight benefit for the female gender, which 
did not attain statistical significance. Given the small 
numbers it is not surprising that none of the variables 
achieved significance. Quality of life studies82,83 were 
not formally carried out in this investigation.
DISCUSSION
These results are comparable to published first world 
outcomes. Our analysis allows four conclusions. Firstly, 
the scientific and ethical aspects of immunohematot
poietic stem cell transplantation, whether the graft is 
derived from bone marrow or peripheral blood, when 
conducted by an appropriately constituted and funct
tioning multidisciplinary team, operating in a private 
academic center, demonstrably meets worldwide stant
dards of practice. This is reflected in satisfactory audit 
with ongoing retaccreditation of this particular team 
by the International and Autologous Bone Marrow 
Transplant Registries now combined as the Centre for 
International Blood and Marrow Transplant Research 
with endorsement as a transplant, harvest and donor 
center by the European Group for Blood and Bone 
Marrow Transplantation as well as for performing 
these procedures as designated by the North American 
National Marrow Donor Program.
Secondly, while indications continue to undergo 
redefinition, correct case selection is imperative, if the 
best needs of the community are to be served. Thus, act
cess to the technology must be widely available and, by 
definition, this includes responsible resource allocation 
between state and private sectors. To this end it is cont
structive to contrast the present experience to our init
tial reports10t12 that were recently updated from a state 
hospital.13 It can be seen that there is no substantial dift
ference in demography, procedure or results other than, 
in the current series, somewhat larger numbers, wider 
indications, use of intravenous busulphan and inclusion 
of matched unrelated volunteer donors. Of relevance is 
that, at least in siblings, further immunosuppression is 
not needed after ex vivo Ttcell depletion and this transt
lates to financial cost saving with possibly a decrease in 
morbidity. It therefore follows that even when alternative 
graft sources are used, the relatively high initial costs are 
clearly offset by the potential for cure and so justify the 
maintenance and indeed ongoing development of such 
a therapeutic option. This situation differs significantly 
from regimens using unmanipulated grafts which would 
then typically include cyclosporine A, shorttcourse 
methotrexate and often corticosteroids as necessary 
to control rejection and blunt acute as well as chronic 
grafttversusthost disease. To accommodate these varit
ables identification of teams that fully and consistently 
meet standards, of which the centerteffect necessitating 
a minimal number of procedures to comply with agreed 
activity, is mandatory to prevent this important treatt
ment option becoming discredited as a result of inadt
equate performance. Whether a mechanism for national 
scrutiny and registration can be established is currently 
conceivable but whether it would ever become acceptt
able in the wider world remains moot. Currently at 
least compliance with the approved guidelines from The 
North American Foundation for the Accreditation of 
Hematopoietic Stem Cell Therapy84 as well as the Joint 
Accreditation Committee of the International Society 
for Hematopoietic Therapy and Graft Engineering in 
Europe and the European Group for Blood and Marrow 
Transplantation85 would be a desirable starting point. 
In this context there is also the crucial balance between 
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the undoubted need and funding provided by managed 
health care required to allow private sector programs to 
match state activities with the latter having a reciprot
cal obligation to provide for individuals with limited 
resources. In these circumstances utilization of those 
procedures should be shared on the basis of resource 
availability for individual patient groups.
Thirdly is the crucial caveat that only peertret
viewed protocols, having undergone scrutiny by Ethics 
and Research Committees coupled with Institutional 
Review Board endorsement, are supported. These need, 
in a single center by definition, to have the expertise and 
flexibility to accommodate appropriate patient categot
ries and to do so irrespective of age. Given the constant 
revision of the role that such interventions generate an 
acute awareness of                                     shifting entry int
dications is vital. For example there is now appropriate 
and decreasing referral in acute myeloid leukemia when 
the presence of specific, or good risk, cytogenetic markt
ers show equal outcome with optimum chemotherapy. 
Furthermore, the competing role of small molecules 
such as retinoic acid and arsenic in progranulocytic tut
mors on the one hand and signal transduction inhibit
tion in chronic granulocytic leukemia using imatinib 
on the other, alter the previously automatic inclusion of 
stem cell transplantation in treatment algorithms. There 
needs to be a consciousness that these expensive but pot
tentially curative interventions retain a role in Hodgkin 
and other lymphomas, but outside clinical trials, preft
erably international, raise serious reservations about 
uncritical and random usage. Concerns focus on small 
numbers of cases in unregistered practice by occasional 
therapists not reporting results. Implicit in such ongot
ing scrutiny is an obligation for unit or team recognition 
based upon outcome analysis and peer review accountt
ability raising the spectre of there being some sensible 
restriction to preferred providers or designated units. 
These need to be defined by published survival data and, 
most certainly, not the alternative, but convenient choice 
of only cost as the defining factor for sotcalled preferred 
providers!
Fourthly, among the areas of expanding interest are 
the solid tumors. The present data are too small for 
interpretation and only establish technical feasibility. 
The continuation of this commitment, perhaps more 
so than in conventional usage, should not be restricted 
but rather encouraged, within the context of thoughtful, 
registered and multicenter trials.
CONCLUSION
This interim analysis of ongoing studies presents 
outcomes consistent with international standards 
of practice and supports the appropriateness of cont
tinuing to provide immunohematopoietic stem cell 
transplantation to properly selected cases throughout 
South Africa. This subtSaharan stance could serve as a 
model for other undertresourced countries worldwide. 
Predictably no difference in results could be found bet
tween those from this private academic center or a state 
hospital emphasizing that allocation of transplantation 
should be shared as dictated by availability of resources 
in each sector. Furthermore, since these are uniform irt
respective of age, separate pediatric units are difficult 
to justify in the face of a limited and ever deteriorating 
economic climate. Whilst acknowledging substantial 
financial costs and morbidity and mortality, these are 
offset by the curative potential of this form of treatt
ment and, accordingly, they remain an obligation, but 
should be provided, and fully supported, only in those 
centers that meet stringent international criteria, int
cluding regular audit, and consequently enjoy ongoing 
accreditation by major registries worldwide.
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